Insider Selling: PTC Therapeutics (NASDAQ:PTCT) CFO Sells 2,139 Shares of Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) CFO Pierre Gravier sold 2,139 shares of PTC Therapeutics stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $76.95, for a total transaction of $164,596.05. Following the completion of the transaction, the chief financial officer directly owned 90,310 shares of the company’s stock, valued at $6,949,354.50. This trade represents a 2.31% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

PTC Therapeutics Stock Performance

Shares of NASDAQ:PTCT traded down $0.39 during trading on Thursday, reaching $76.85. 1,625,361 shares of the stock traded hands, compared to its average volume of 1,684,365. The stock has a market cap of $6.17 billion, a P/E ratio of 8.98 and a beta of 0.49. The stock has a 50-day moving average of $76.26 and a two-hundred day moving average of $62.43. PTC Therapeutics, Inc. has a 52-week low of $35.95 and a 52-week high of $87.50.

PTC Therapeutics (NASDAQ:PTCT) last announced its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.19) by $1.39. The company had revenue of $211.01 million during the quarter, compared to analyst estimates of $177.42 million. PTC Therapeutics had a net margin of 42.25% and a negative return on equity of 194.11%. The firm’s revenue for the quarter was up 7.2% on a year-over-year basis. During the same period in the previous year, the business earned ($1.39) EPS. Sell-side analysts expect that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current year.

Institutional Investors Weigh In On PTC Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Wealth Enhancement Advisory Services LLC raised its holdings in PTC Therapeutics by 9.7% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 9,145 shares of the biopharmaceutical company’s stock worth $701,000 after purchasing an additional 806 shares during the period. GAMMA Investing LLC grew its holdings in PTC Therapeutics by 160.0% during the fourth quarter. GAMMA Investing LLC now owns 1,451 shares of the biopharmaceutical company’s stock valued at $110,000 after purchasing an additional 893 shares during the period. IFP Advisors Inc increased its position in PTC Therapeutics by 68.1% in the third quarter. IFP Advisors Inc now owns 765 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 310 shares in the last quarter. Cambria Investment Management L.P. raised its stake in shares of PTC Therapeutics by 24.9% in the third quarter. Cambria Investment Management L.P. now owns 11,634 shares of the biopharmaceutical company’s stock worth $714,000 after buying an additional 2,322 shares during the period. Finally, CIBC Bancorp USA Inc. bought a new position in shares of PTC Therapeutics in the third quarter worth about $508,000.

PTC Therapeutics News Roundup

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Recent fundamentals still supportive — PTC reported an earnings and revenue beat in its last quarter (Nov.) and maintains strong margins relative to peers, which underpins the stock’s valuation and analyst interest. MarketBeat PTCT profile
• Neutral Sentiment: Small inducement grant: the company approved 300 restricted stock units for a new non‑executive employee on Jan. 2 — immaterial dilution and likely not a major near‑term driver. PR Newswire: Inducement Grants
• Neutral Sentiment: Analyst consensus is a “Hold” with a mixed set of price targets and ratings — this produces limited conviction among buy‑side actors and can temper short‑term moves. Analyst consensus report
• Negative Sentiment: Heavy insider selling disclosed in multiple Form 4s — several executives and directors (including the CEO, CFO, EVP, VPs and others) sold several tens of thousands of shares across Jan. 6–7 at ~\$77 per share, representing millions of dollars of proceeds. Collective insider sales at this scale can put near‑term downward pressure on the stock and signal to some investors that insiders are taking gains. The filings and aggregated alert are here for review. InsiderTrades: Jan. insider sales alert

Analysts Set New Price Targets

Several equities research analysts recently commented on PTCT shares. Wall Street Zen raised PTC Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, January 3rd. The Goldman Sachs Group upped their target price on shares of PTC Therapeutics from $44.00 to $50.00 and gave the company a “sell” rating in a research note on Wednesday, November 5th. Barclays raised their price target on shares of PTC Therapeutics from $46.00 to $68.00 and gave the company an “equal weight” rating in a report on Wednesday, November 5th. TD Cowen boosted their price objective on shares of PTC Therapeutics from $50.00 to $63.00 and gave the company a “hold” rating in a report on Wednesday, November 5th. Finally, Morgan Stanley restated an “overweight” rating and set a $90.00 price objective on shares of PTC Therapeutics in a research report on Thursday. Nine equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $77.27.

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.